Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
135.44
-2.87 (-2.08%)
At close: Jul 22, 2026, 4:00 PM EDT
135.44
0.00 (0.00%)
Pre-market: Jul 23, 2026, 7:25 AM EDT
Protagonist Therapeutics Stock Forecast
Stock Price Forecast
According to 13 analysts polled by S&P Global, Protagonist Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $125.15. The average 1-year stock price forecast is 7.60% lower than the current stock price, while the lowest is $100 (-26.17%) and the highest is $165 (+21.83%).
Price Target: $125.15 (-7.60%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Protagonist Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 9 | 9 | 9 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens JMP | Citizens JMP | Buy Maintains $137 → $165 | Buy | Maintains | $137 → $165 | +21.83% | Jul 17, 2026 |
Unknown Analyst Jefferies No rating | Jefferies | Buy Maintains $121 | Buy | Maintains | $121 | -10.66% | Jul 16, 2026 |
| Truist Financial | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jul 16, 2026 |
| Barclays | Barclays | Buy Maintains $119 → $151 | Buy | Maintains | $119 → $151 | +11.49% | Jul 14, 2026 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $97 → $110 | Hold | Maintains | $97 → $110 | -18.78% | Jun 11, 2026 |
Financial Forecast
Revenue This Year
528.25M
from 46.02M
Increased by 1,047.97%
Revenue Next Year
188.13M
from 528.25M
Decreased by -64.39%
EPS This Year
4.47
from -2.05
EPS Next Year
-0.19
from 4.47
EPS and Forward PE are based on non-GAAP adjusted numbers.